Literature DB >> 21146666

Impact of left ventricular systolic function on clinical and echocardiographic outcomes following transcatheter aortic valve implantation for severe aortic stenosis.

See Hooi Ewe1, Nina Ajmone Marsan, Mauro Pepi, Victoria Delgado, Gloria Tamborini, Manuela Muratori, Arnold C T Ng, Frank van der Kley, Arend de Weger, Martin J Schalij, Melissa Fusari, Paolo Biglioli, Jeroen J Bax.   

Abstract

BACKGROUND: This study aimed to evaluate the impact of baseline left ventricular (LV) systolic function on clinical and echocardiographic outcomes following transcatheter aortic valve implantation (TAVI). Survival of patients undergoing TAVI was also compared with that of a population undergoing surgical aortic valve replacement.
METHODS: One hundred forty-seven consecutive patients (mean age=80±7 years) undergoing TAVI in 2 centers were included. Mean follow-up period was 9.1±5.1 months.
RESULTS: At baseline, 34% of patients had impaired LV ejection fraction (LVEF) (<50%) and 66% had normal LVEF (≥50%). Procedural success was similar in these 2 groups (94% vs 97%, P=.41). All patients achieved improvement in transvalvular hemodynamics. At follow-up, patients with a baseline LVEF<50% showed marked LV reverse remodeling, with improvement of LVEF (from 37%±8% to 51%±11%). Early and late mortality rates were not different between the 2 groups, despite a higher rate of combined major adverse cardiovascular events (MACEs) in patients with a baseline LVEF<50%. The predictors of cumulative MACEs were baseline LVEF (HR=0.97, 95% CI=0.94-0.99) and preoperative frailty (HR=4.20, 95% CI=2.00-8.84). In addition, long-term survival of patients with impaired or normal LVEF was comparable with that of a matched population who underwent surgical aortic valve replacement.
CONCLUSIONS: TAVI resulted in significant improvement in LV function and survival benefit in high-risk patients with severe aortic stenosis, regardless of baseline LVEF. Patients with a baseline LVEF<50% were at higher risk of combined MACEs.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21146666     DOI: 10.1016/j.ahj.2010.09.003

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  32 in total

Review 1.  Transcatheter valve interventions in heart failure: new answers to old questions.

Authors:  Marijana Tadic; Cesare Cuspidi
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

2.  Transcatheter aortic valve implantation: Current status and future perspectives.

Authors:  Pablo Salinas; Raul Moreno; Jose L Lopez-Sendon
Journal:  World J Cardiol       Date:  2011-06-26

3.  Improvement of left ventricular longitudinal systolic function after transcatheter aortic valve implantation: a speckle-tracking prospective study.

Authors:  Flavio D'Ascenzi; Matteo Cameli; Alessandro Iadanza; Matteo Lisi; Valerio Zacà; Rosanna Reccia; Valeria Curci; Andrea Torrisi; Giuseppe Sinicropi; Carlo Pierli; Sergio Mondillo
Journal:  Int J Cardiovasc Imaging       Date:  2012-12-28       Impact factor: 2.357

4.  Transcatheter aortic valve implantation in patients with severely reduced left ventricular systolic function: a single-center experience.

Authors:  Mohamed El-Mawardy; Nora Wübken-Kleinfeld; Bettina Schwarz; Ken Gordian; Björn Stöcker; Holger Sier; Ralph Toelg; Volker Geist; Ernst-Günther Kraatz; Gert Richardt; Mohamed Abdel-Wahab
Journal:  Clin Res Cardiol       Date:  2014-03-11       Impact factor: 5.460

5.  The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience.

Authors:  Philip Green; Abigail E Woglom; Philippe Genereux; Benoit Daneault; Jean-Michel Paradis; Susan Schnell; Marian Hawkey; Mathew S Maurer; Ajay J Kirtane; Susheel Kodali; Jeffrey W Moses; Martin B Leon; Craig R Smith; Mathew Williams
Journal:  JACC Cardiovasc Interv       Date:  2012-09       Impact factor: 11.195

6.  Relation of frailty to outcomes after transcatheter aortic valve replacement (from the PARTNER trial).

Authors:  Philip Green; Suzanne V Arnold; David J Cohen; Ajay J Kirtane; Susheel K Kodali; David L Brown; Charanjit S Rihal; Ke Xu; Yang Lei; Marian C Hawkey; Rebeca J Kim; Maria C Alu; Martin B Leon; Michael J Mack
Journal:  Am J Cardiol       Date:  2015-04-18       Impact factor: 2.778

7.  The Influence of Frailty on Outcomes in Cardiovascular Disease.

Authors:  Matthew Finn; Philip Green
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2015-06-27

Review 8.  Frailty, Aging, and Cardiovascular Surgery.

Authors:  Antonio Graham; Charles H Brown
Journal:  Anesth Analg       Date:  2017-04       Impact factor: 5.108

Review 9.  Frailty assessment in the cardiovascular care of older adults.

Authors:  Jonathan Afilalo; Karen P Alexander; Michael J Mack; Mathew S Maurer; Philip Green; Larry A Allen; Jeffrey J Popma; Luigi Ferrucci; Daniel E Forman
Journal:  J Am Coll Cardiol       Date:  2013-11-27       Impact factor: 24.094

Review 10.  Practical approach on frail older patients attended for acute heart failure.

Authors:  Francisco J Martín-Sánchez; Michael Christ; Òscar Miró; W Frank Peacock; John J McMurray; Héctor Bueno; Alan S Maisel; Louise Cullen; Martin R Cowie; Salvatore Di Somma; Elke Platz; Josep Masip; Uwe Zeymer; Christiaan Vrints; Susanna Price; Christian Mueller
Journal:  Int J Cardiol       Date:  2016-07-18       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.